Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia

INTRODUCTION: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS). However, there are no consistent data...

Descripción completa

Detalles Bibliográficos
Autores principales: Górgolas Hernández-Mora, Miguel, Cabello Úbeda, Alfonso, Prieto-Pérez, Laura, Villar Álvarez, Felipe, Álvarez Álvarez, Beatriz, Rodríguez Nieto, María Jesús, Carrillo Acosta, Irene, Fernández Ormaechea, Itziar, Al-Hayani, Aws Waleed Mohammed, Carballosa, Pilar, Calpena Martínez, Silvia, Ezzine, Farah, Castellanos González, Marina, Naya, Alba, López De Las Heras, Marta, Rodríguez Guzmán, Marcel José, Cordero Guijarro, Ana, Broncano Lavado, Antonio, Macías Valcayo, Alicia, Martín García, Marta, Bécares Martínez, Javier, Fernández Roblas, Ricardo, Piris Pinilla, Miguel Ángel, Fortes Alen, José, Sánchez Pernaute, Olga, Romero Bueno, Fredeswinda, Heili-Frades, Sarah, Peces-Barba Romero, Germán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585732/
https://www.ncbi.nlm.nih.gov/pubmed/33115682
http://dx.doi.org/10.1016/j.ijid.2020.10.045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585732/
https://www.ncbi.nlm.nih.gov/pubmed/33115682
http://dx.doi.org/10.1016/j.ijid.2020.10.045

Ejemplares similares